Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors

Authors: Oreekha Amin, Marie-Claude Beauchamp, Paul Abou Nader, Ido Laskov, Sanaa Iqbal, Charles-André Philip, Amber Yasmeen, Walter H. Gotlieb

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Impairment of homologous recombination (HR) is found in close to 50 % of ovarian and breast cancer. Tumors with BRCA1 mutations show increased expression of the Insulin-like growth factor type 1 receptor (IGF-1R). We previously have shown that inhibition of IGF-1R results in growth inhibition and apoptosis of ovarian tumor cells. In the current study, we aimed to investigate the correlation between HR and sensitivity to IGF-1R inhibition. Further, we hypothesized that IGF-1R inhibition might sensitize HR proficient cancers to Poly ADP ribose polymerase (PARP) inhibitors.

Methods

Using ovarian and breast cancer cellular models with known BRCA1 status, we evaluated their HR functionality by RAD51 foci formation assay. The 50 % lethal concentration (LC50) of Insulin-like growth factor type 1 receptor kinase inhibitor (IGF-1Rki) in these cells was assessed, and western immunoblotting was performed to determine the expression of proteins involved in the IGF-1R pathway. Moreover, IGF-1R inhibitors were added on HR proficient cell lines to assess mRNA and protein expression of RAD51 by qPCR and western blot. Also, we explored the interaction between RAD51 and Insulin receptor substance 1 (IRS-1) by immunoprecipitation. Next, combination effect of IGF-1R and PARP inhibitors was evaluated by clonogenic assay.

Results

Cells with mutated/methylated BRCA1 showed an impaired HR function, and had an overactivation of the IGF-1R pathway. These cells were more sensitive to IGF-1R inhibition compared to HR proficient cells. In addition, the IGF-IR inhibitor reduced RAD51 expression at mRNA and protein levels in HR proficient cells, and sensitized these cells to PARP inhibitor.

Conclusion

Targeting IGF-1R might lead to improved personalized therapeutic approaches in cancer patients with HR deficiency. Targeting both PARP and IGF-1R might increase the clinical efficacy in HR deficient patients and increase the population of patients who may benefit from PARP inhibitors.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res. 2013;19:6380–8.CrossRefPubMed
3.
Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake 2nd DD, et al. Somatic mutations in brca1 and brca2 could expand the number of patients that benefit from poly (adp ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28:3570–6.CrossRefPubMedPubMedCentral
4.
Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of brca mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082–9.CrossRefPubMedPubMedCentral
5.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene brca1. Science. 1994;266:66–71.CrossRefPubMed
6.
7.
Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, et al. Prevalence of brca1 and brca2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150:71–80.CrossRefPubMed
8.
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene brca2. Nature. 1995;378:789–92.CrossRefPubMed
9.
Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4:511–8.CrossRefPubMed
10.
Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of brca1 function in a defined tumor cell line. Mol Cell. 1999;4:1093–9.CrossRefPubMed
11.
McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(adp-ribose) polymerase inhibition. Cancer Res. 2006;66:8109–15.CrossRefPubMed
12.
Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT, et al. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among brca1 and brca2 carriers. Breast Cancer Res. 2009;11:R76.CrossRefPubMedPubMedCentral
13.
Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, et al. Intratumoral igf-i protein expression is selectively upregulated in breast cancer patients with brca1/2 mutations. Endocr Relat Cancer. 2007;14:1053–62.CrossRefPubMed
14.
Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, et al. Elevated insulin-like growth factor-i receptor (igf-ir) levels in primary breast tumors associated with brca1 mutations. Cancer Lett. 2007;257:236–43.CrossRefPubMed
15.
Pasanisi P, Bruno E, Venturelli E, Manoukian S, Barile M, Peissel B, et al. Serum levels of igf-i and brca penetrance: A case control study in breast cancer families. Fam Cancer. 2011;10:521–8.CrossRefPubMed
16.
Beck EP, Russo P, Gliozzo B, Jaeger W, Papa V, Wildt L, et al. Identification of insulin and insulin-like growth factor i (igf i) receptors in ovarian cancer tissue. Gynecol Oncol. 1994;53:196–201.CrossRefPubMed
17.
Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, et al. Igf-i in epithelial ovarian cancer and its role in disease progression. Growth Factors. 2007;25:346–54.CrossRefPubMed
18.
Karasik A, Menczer J, Pariente C, Kanety H. Insulin-like growth factor-i (igf-i) and igf-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab. 1994;78:271–6.PubMed
19.
Weigang B, Nap M, Bittl A, Jaeger W. Immunohistochemical localization of insulin-like growth factor 1 receptors in benign and malignant tissues of the female genital tract. Tumour Biol. 1994;15:236–46.CrossRefPubMed
20.
Yee D, Morales FR, Hamilton TC, Von Hoff DD. Expression of insulin-like growth factor i, its binding proteins, and its receptor in ovarian cancer. Cancer Res. 1991;51:5107–12.PubMed
21.
22.
Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, et al. Insulin-like growth factor receptor i targeting in epithelial ovarian cancer. Gynecol Oncol. 2006;100:389–96.CrossRefPubMed
23.
Resnicoff M, Ambrose D, Coppola D, Rubin R. Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest. 1993;69:756–60.PubMed
24.
Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, Pollak MN, et al. Bms-536924 sensitizes human epithelial ovarian cancer cells to the parp inhibitor, 3-aminobenzamide. Gynecol Oncol. 2009;115:193–8.CrossRefPubMed
25.
Beauchamp MC, Yasmeen A, Knafo A, Gotlieb WH. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol. 2010;2010:257058.CrossRefPubMedPubMedCentral
26.
An Y, Cai Y, Guan Y, Cai L, Yang Y, Feng X, et al. Inhibitory effect of small interfering rna targeting insulin-like growth factor-i receptor in ovarian cancer ovcar3 cells. Cancer Biother Radiopharm. 2010;25:545–52.CrossRefPubMed
27.
27 Hartog H, Boezen HM, de Jong MM, Schaapveld M, Wesseling J, van der Graaf WT. Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer. Breast (Edinburgh, Scotland) 2013;22:1155–1160.
28.
28 Davison Z, de Blacquiere GE, Westley BR, May FE. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: Implications for therapy. Neoplasia (New York, NY) 2011;13:504–515.
29.
Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D. The type i insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene. 2010;29:251–62.CrossRefPubMed
30.
Saldana SM, Lee HH, Lowery FJ, Khotskaya YB, Xia W, Zhang C, et al. Inhibition of type i insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLoS ONE. 2013;8:e73406.CrossRefPubMedPubMedCentral
31.
Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene. 2010;29:2517–27.CrossRefPubMedPubMedCentral
32.
Chitnis MM, Lodhia KA, Aleksic T, Gao S, Protheroe AS, Macaulay VM. Igf-1r inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination. Oncogene. 2013.
33.
Cosaceanu D, Carapancea M, Castro J, Ekedahl J, Kanter L, Lewensohn R, et al. Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett. 2005;222:173–81.CrossRefPubMed
34.
Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et al. Brca1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res. 2006;66:41–5.CrossRefPubMed
35.
Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, et al. Brca1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious brca1 mutation. Mol Oncol. 2013;7:567–79.CrossRefPubMedPubMedCentral
36.
Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, et al. Pi3k inhibition impairs brca1/2 expression and sensitizes brca-proficient triple-negative breast cancer to parp inhibition. Cancer Discovery. 2012;2:1036–47.CrossRefPubMed
37.
Maor S, Papa MZ, Yarden RI, Friedman E, Lerenthal Y, Lee SW, et al. Insulin-like growth factor-i controls brca1 gene expression through activation of transcription factor sp1. Horm Metab Res. 2007;39:179–85.CrossRefPubMed
38.
Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315–9.CrossRefPubMed
39.
Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 2010;70:440–6.CrossRefPubMed
40.
RL OD, McCormick A, Mukhopadhyay A, Woodhouse LC, Moat M, Grundy A, et al. The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis. PLoS ONE. 2014;9:e90604.CrossRef
41.
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(adp-ribose) polymerase in tumors from brca mutation carriers. N Engl J Med. 2009;361:123–34.CrossRefPubMed
42.
Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in brca1-mutation carriers. Breast cancer linkage consortium. Am J Hum Genet. 1995;56:265–71.CrossRefPubMedPubMedCentral
43.
Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of brca1 and brca2 among ashkenazi jews. N Engl J Med. 1997;336:1401–8.CrossRefPubMed
44.
45.
Abramovitch S, Glaser T, Ouchi T, Werner H. Brca1-sp1 interactions in transcriptional regulation of the igf-ir gene. FEBS Lett. 2003;541:149–54.CrossRefPubMed
46.
Amichay K, Kidron D, Attias-Geva Z, Schayek H, Sarfstein R, Fishman A, et al. Brca1 is expressed in uterine serous carcinoma (usc) and controls insulin-like growth factor i receptor (igf-ir) gene expression in usc cell lines. Int J Gynecol Cancer. 2012;22:748–54.CrossRefPubMed
47.
Attias-Geva Z, Bentov I, Kidron D, Amichay K, Sarfstein R, Fishman A, et al. P53 regulates insulin-like growth factor-i receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-i receptor-directed targeted therapy. Eur J Cancer. 2012;48:1570–80.CrossRefPubMed
48.
Shukla V, Coumoul X, Cao L, Wang RH, Xiao C, Xu X, et al. Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members. Cancer Res. 2006;66:7151–7.CrossRefPubMed
49.
Lodhia KA, Gao S, Aleksic T, Esashi F, Macaulay VM. Suppression of homologous recombination sensitizes human tumor cells to igf-1r inhibition. Int J Cancer. 2015;136(12):2961–6. doi:10.​1002/​ijc.​29327.CrossRefPubMed
50.
51.
Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (cp-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol. 2009;4:1397–403.CrossRefPubMedPubMedCentral
52.
Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P. Meijers M, et al. Clin Cancer Res: Functional ex vivo assay to select homologous recombination deficient breast tumors for parp inhibitor treatment; 2014.
53.
Trojanek J, Ho T, Del Valle L, Nowicki M, Wang JY, Lassak A, et al. Role of the insulin-like growth factor i/insulin receptor substrate 1 axis in rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol. 2003;23:7510–24.CrossRefPubMedPubMedCentral
54.
Wang Y, Yuan JL, Zhang YT, Ma JJ, Xu P, Shi CH, et al. Inhibition of both egfr and igf1r sensitized prostate cancer cells to radiation by synergistic suppression of DNA homologous recombination repair. PLoS ONE. 2013;8:e68784.CrossRefPubMedPubMedCentral
55.
Turney BW, Kerr M, Chitnis MM, Lodhia K, Wang Y, Riedemann J, et al. Depletion of the type 1 igf receptor delays repair of radiation-induced DNA double strand breaks. Radiother Oncol. 2012;103:402–9.CrossRefPubMed
Metadata
Title
Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
Authors
Oreekha Amin
Marie-Claude Beauchamp
Paul Abou Nader
Ido Laskov
Sanaa Iqbal
Charles-André Philip
Amber Yasmeen
Walter H. Gotlieb
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1803-y

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Study protocol

Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial)

Research article

Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case

Research article

Phage display screening identifies a novel peptide to suppress ovarian cancer cells in vitro and in vivo in mouse models

Case report

The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer

Research article

DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells

Study protocol

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits